Characterization of human mesenchymal stem cells from Ewing sarcoma patients. Pathogenetic implications

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Amaral, Ana Teresa A ^a,d   Manara, Maria Cristina ^b   Berghuis, Dagmar ^c   Ordóñez, José Luis ^a   Biscuola, Michele ^d   Lopez García, Maria Angeles ^d   Osuna, Daniel ^a   Lucarelli, Enrico ^b   Alviano, Francesco ^b   Lankester, Arjan ^c   Scotlandi, Katia ^b   De Álava, Enriquede ^a,d  

^a Centro de Investigacion del Cancer   (Spain)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; CD99 ANTIBODY; CD99 ANTIGEN; CELL ANTIBODY; ENDOGLIN; THY 1 ANTIGEN; UNCLASSIFIED DRUG; CALMODULIN BINDING PROTEIN; CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; EWS-FLI FUSION PROTEIN; EWSR1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; ONCOPROTEIN; PTPRC PROTEIN, HUMAN; RNA BINDING PROTEIN; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR FLI 1;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EWING SARCOMA; EWS FLI1 GENE; EWSR1 GENE; GENE FUSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; ONCOGENE; PATHOGENESIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMAGENESIS; SCHOOL CHILD; YOUNG ADULT; CELL CULTURE; CELL LINE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY;

ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, CD45; ANTIGENS, THY-1; CALMODULIN-BINDING PROTEINS; CELL ADHESION MOLECULES; CELL LINE; CELLS, CULTURED; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MESENCHYMAL STROMAL CELLS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEIN EWS; RNA-BINDING PROTEINS; SARCOMA, EWING;

EID: 84895474171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085814     Document Type: Article

References (36)

1. Riggi N, Stamenkovic I (2007) The Biology of Ewing sarcoma. Cancer Lett 254: 1-10. (Pubitemid 47058800)
2. Ordonez JL, Osuna D, Garcia-Dominguez DJ, Amaral AT, Otero-Motta AP, et al. (2010) The clinical relevance of molecular genetics in soft tissue sarcomas. Adv Anat Pathol 17: 162-181.
3. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J (2009) Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res 69: 7140-7150.
4. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, et al. (2005) Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65: 11459-11468. (Pubitemid 41821703)
5. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, et al. (2010) EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 24: 916-932.
6. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, et al. (2007) Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11: 421-429. (Pubitemid 46680428)
7. Toomey EC, Schiffman JD, Lessnick SL (2010) Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 29: 4504-4516.
8. von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, et al. (2011) Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS ONE 6: e19305.
9. Ross KA, Smyth NA, Murawski CD, Kennedy JG (2013) The biology of ewing sarcoma. ISRN Oncol 759725.
10. Lin PP, Wang Y, Lozano G (2011) Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma 2011: 8.
11. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, et al. (2008) Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 28: 2125-2137. (Pubitemid 351429961)
12. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, et al. (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219: 294-305.
13. Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, et al. (2010) Synovial sarcoma is a stem cell malignancy. Stem Cells 28: 1119-1131.
14. Rodriguez R, Rubio R, Gutierrez-Aranda I, Melen GJ, Elosua C, et al. (2011) Fus-Chop Fusion Protein Expression Coupled to P53 Deficiency Induces Liposarcoma in Mouse but not Human Adipose-Derived Mesenchymal Stem/Stromal Cells. Stem Cells 29: 179-179.
15. Rubio R, Garcia-Castro J, Gutierrez-Aranda I, Paramio J, Santos M, et al. (2010) Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 70: 4185-4194.
16. Kauer M, Ban J, Kofler R, Walker B, Davis S, et al. (2009) A molecular function map of Ewing's sarcoma. PLoS ONE 4: e5415.
17. Li N, Yang R, Zhang W, Dorfman H, Rao P, et al. (2009) Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer 115: 4795-4806.
18. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, et al. (2009) Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 23: 1515-1527.
19. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, et al. (2009) Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 23: 664-672.
20. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, et al. (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49: 40-51.
21. Lopez-Beltran A, Ordonez JL, Otero AP, Blanca A, Sevillano V, et al. (2010) Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch 457: 555-561.
22. Gelin C ZM, Jovanovich D and Boumsell L (1995) Leucocyte, Typing V. White Cell Differentiation Antigens. Proceedings of the Fifth International Workshop and Conference Oxford University Press: Oxford, England.
23. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317. (Pubitemid 44269669)
24. Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, et al. (2006) Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 12: 3532-3540.
25. Landuzzi L, De Giovanni C, Nicoletti G, Rossi I, Ricci C, et al. (2000) The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol 157: 2123-2131.
26. Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, et al. (2003) C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 21: 1952-1960. (Pubitemid 46606383)
27. Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, et al. (2000) CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 60: 5134-5142.
28. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, et al. (2004) Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 23: 5664-5674. (Pubitemid 39093044)
29. Johnson JJ, Chen W, Hudson W, Yao Q, Taylor M, et al. (2003) Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia. Blood 101: 3229-3235. (Pubitemid 36858019)
30. Kovar H (2005) Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 15: 189-196.
31. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, et al. (2011) Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 28: 3284-3291.
32. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, et al. (2005) EWSFLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res 65: 4633-4644. (Pubitemid 40740799)
33. Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, et al. (2010) CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest 120: 668-680.
34. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, et al. (2006) Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer 42: 91-96. (Pubitemid 41814537)
35. Bacci G, Boriani S, Balladelli A, Barbieri E, Longhi A, et al. (2009) Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution. Eur Spine J 18: 1091-1095.
36. Scotlandi K (2006) Targeted therapies in Ewing's sarcoma. Adv Exp Med Biol 587: 13-22.